Cite
HARVARD Citation
Morris, A. et al. (n.d.). 604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma. Journal for immunotherapy of cancer. pp. A360-A361. [Online].